Healthy neu-N mice were injected intravenously with 15, 22, 30, and 44 KBq of Ac225-anti-PD-L1-BC. The mice were sacrificed when one of three conditions were met: >20% weight loss, evidence of pain or distress, the 100 day endpoint was reached. The liver, spleen, kidneys, and thymus were removed and sectioned for imaging with an alpha camera [see next paper for a description of an alpha camera].
Liver and spleen received the highest doses: 738 and 615 mGy/kBq respectively. The kidneys received 138 mGy/kBq. The dose was uniform in the liver so macrodosimetry should give an accurate measure and the liver will determine the maximum tolerated dose. Activity was very non-uniform in the kidneys, spleen, and thymus. In the case of the kidneys, the non-uniformity may be attributed to a substantial contribution of the Bi213 which is preferentially absorbed in the renal cortex
Presented By: Anders Josefsson from Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.